The method transfers. What about the judgment?

Every organization has one or two. A scientist who understands the chemistry at a level almost nobody else does. They designed the method. They know why the molecule degrades the way it does.

Then the work goes to a CRO or a CDMO. The method transfers, the SOP transfers, and the person who wrote both stays here.

The reviews that matter aren't pass or fail. A shoulder on a peak. An impurity that shouldn't be there. A result sitting just inside spec. Reading those takes the chemistry, not just the acceptance criteria.

So you read the spreadsheets. You hold the call. You ask questions designed to find out whether someone else saw what your scientist would have seen. It's a reasonable process. It is also slow, and it never fully closes.

That scientist can now teach a model how they read the data, from their own reviewed examples and their own SOPs. The model runs inside the partner lab and applies that standard to every sample off the instrument. Routine clears. Exceptions reach them the moment they appear, whether the flag points to sample prep, the instrument, or the science.

Review by exception, wherever the method runs. Your scientist isn't reviewing samples in three labs. They're resolving the handful that need them while the run is still going, with both organizations seeing the same thing.
For the people around the table, that means everyone is reading the data the same way. Review cycles shorten, problems surface earlier, and decisions stop waiting on interpretation. In drug development, a decision made sooner is capital that stops sitting still.

How many labs does your best scientist need to be in right now?

#AnalyticalChemistry #DrugDevelopment #ExpertIntelligence hashtag#MethodTransfer #CDMO #CRO